A new method to assay protease based on amyloid misfolding: Application to prostate cancer diagnosis using a panel of proteases biomarkers

Theranostics

Volumn 4, Issue 7, 2014, Pages 701-707

  Li, Hao ^a   Huang, Yue ^a   Zhang, Bin ^b   Yang, Dawei ^a   Zhu, Xiaoli ^b   Li, Genxi ^a,b  

^a NANJING UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY   (China)

Author keywords

Amyloid misfolding; Biomarker; Electrochemical detection; Prostate cancer; Protease

Indexed keywords

AMYLOID; KALLIKREIN; KALLIKREIN 2; MATRIPTASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; SERINE PROTEINASE; TISSUE KALLIKREIN;

ARTICLE; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; ELECTROCHEMISTRY; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; ISOTHERMAL TITRATION CALORIMETRY; MALE; PROCESS OPTIMIZATION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MOTIF; ROOM TEMPERATURE; BLOOD; CASE CONTROL STUDY; CHEMISTRY; EARLY DIAGNOSIS; PROCEDURES; PROSTATIC NEOPLASMS; PROTEIN DEGRADATION;

AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN FOLDING; PROTEOLYSIS; SERINE ENDOPEPTIDASES; TISSUE KALLIKREINS;

EID: 84902467166     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8803     Document Type: Article

References (27)

1. Hong B, Zu Y. detecting circulating tumor cells: current challenges and new trends. Theranostics. 2013; 3: 377-394.
2. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer. 2006; 6: 961-967.
3. Hu Z, Lausted C, Yoo H. Quantitative liver-specific protein fingerprint in blood: a signature for hepatotoxicity. Theranostics. 2014; 4: 215-228.
4. Novák J, Kružliak P, Bienertová-Vašků J, et al. MicroRNA-206: a promising theranostic marker. Theranostics. 2014; 4: 119-133.
5. Diamandis EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. Clin Chem. 2013; 59: 147-157.
6. Tufman A, Tian F, Huber R. Can microRNAs improve the management of lung cancer patients? a clinician's perspective. Theranostics. 2013; 3: 953-963.
7. Shapiro J, Nason KS, Davison JM, et al. Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. Ong. J Clin Oncol. 2013; 31: 1576-1582.
8. Storr SJ, Carragher NO, Frame MC. The calpain system and cancer. Nat Rev Cancer. 2011; 1: 364-374.
9. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 2007; 7: 800-808.
10. Kim J, Kim Y. Analysis of protease activity using quantum dots and resonance energy transfer. Theranostics. 2012; 2: 127-138.
11. Yang K, Zhu L, Nie L, et al. Visualization of protease activity in vivo using an activatable photo-acoustic imaging probe based on CuS nanoparticles. Theranostics, 2014; 4: 134-141.
12. Shih PM, Liu TK, Tan KT. Fluorescence amplified detection of proteases by the catalytic activation of a semisynthetic sensor. Chem Comm. 2013; 49: 6212-6214.
13. Chen H, Mei Q, Hou Y, et al. Fabrication of a protease sensor for caspase-3 activity detection based on surface plasmon resonance. Analyst. 2013; 138: 5757-5761.
14. Garai K, Frieden C. Quantitative analysis of the time course of A beta oligomerization and subsequent growth steps using tetramethylrhodamine-labeled A beta. Pro Nat Acad Sci USA. 2013; 110: 3321-3326.
15. Lowe TL, Strzelec A, Kiessling LL. Structure-function relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry, 2001; 40: 7882-7889.
16. Li G, Miao P. Electrochemical analysis of proteins and cells. Berlin, Germany:Springer; 2012.
17. Chelmowski R, Koster SD, Kerstan A, et al. Peptide-based SAMs that resist the absorption of proteins. J Am Chem Soc. 2008; 130: 14952-14953.
18. Saleem M, Adhami VM, Zhong WX, et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidem Biomar. 2006; 15: 217-227.
19. Tripathi M, Potdar AA, Yamashita H, et al. Laminin-332 cleavage by matriptase alters motility parameters of prostate. Cancer Cells. Prostate. 2011; 71: 184-196.
20. Mize GJ, Wang WB, Takayama TK. Prostate-specific kallikreins-2 and-4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and-2. Mol Cancer Res. 2008; 6: 1043-1051.
21. Vickers AJ, Gupta A, Savage CJ, et al. A Panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidem Biomar. 2011; 20: 255-261.
22. Beliveau F, Desilets A, Leduc R. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides. FEBS Journal. 2009; 276: 2213-2226.
23. Cloutier SM, Chagas JR, Mach JP, et al. Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur J Biochem. 2002; 269: 2747-2754.
24. Coombs GS, Bergstrom RC, Pellequer JL, et al. Substrate specificity of prostate-specific antigen (PSA). Chem Biol. 1998; 5: 475-488.
25. Kummer MP, Hermes M, Delekarte A, et al. Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. Neuron. 2011; 71: 833-844.
26. Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin. Chem. 2008; 54: 1600-1607.
27. Parekh DJ, Ankerst DP, Troyer D, et al. Biomarkers for prostate cancer detection. J. urol. 2007; 178: 2252-2259.